RxSight Faces Dual Securities Class Actions After 70% Stock Collapse

RxSight, Inc., a medical technology company specializing in light adjustable intraocular lenses for cataract surgery, is facing multiple securities fraud lawsuits following significant declines in its Light Delivery Device (LDD) sales and overall revenue. The company disclosed adoption challenges and lowered its full-year 2025 revenue guidance, triggering a 37% stock drop in July 2025, following an earlier 38% decline in April after cutting its revenue forecast. Lawsuits, including Makaveev v. RxSight, allege that RxSight and its executives misled investors by overstating product demand and concealing ongoing adoption issues since 2024, which misrepresented the company's financial health and prospects. Additionally, scrutiny has been placed on insider transactions by company directors who sold shares at peak prices before the negative disclosures. These developments have led to investigations by prominent law firms Berger Montague PC, Faruqi & Faruqi LLP, and Bleichmar Fonti & Auld LLP, encouraging investors to seek lead plaintiff status or discuss legal options before the September 22, 2025 deadline. The case underscores broader risks in the healthcare technology and biotech sectors linked to governance failures, market volatility, and regulatory scrutiny.